Does It Really Matter if the Government Helped Develop Moderna's Vaccine?

Moderna (NASDAQ: MRNA) is having issues with the National Institutes of Health, which claims that three of its scientists should be named on the company's patent for its COVID-19 vaccine. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli go into more detail about the dispute, which has not affected the stock price much.

The duo conclude that investors should be more worried about other issues facing the company's COVID-19 vaccine, including the lowered sales projections for the year and its delay in filing for Emergency Use Authorization (EUA) in children.

Source Fool.com